欧洲动物实验的非技术摘要有没有得到改善? 一个更新更新
Katy Taylor1, Tilo Weber2, Laura Rego Alvarez1
1Cruelty Free Europe, Brussels, Belgium.
ALTEX
|March 16, 2024
概括
动物研究的非技术项目摘要 (NTS) 的质量有所提高,但对不良影响的报告仍然不足. 为了有效支持3R和基于证据的政策制定,NTS需要进一步的增强.
科学领域:
- 动物研究伦理 动物研究伦理
- 科学领域的监管合规性
- 科学报告标准 科学报告标准
背景情况:
- 欧盟指令2010/63/EU授权公共NTS用于欧盟的动物研究项目.
- 之前的审查发现了NTS可访问性和质量的缺陷,特别是在不良影响报告方面.
- 尽管英国退出欧盟,但它仍在继续使用相同的NTS模板.
研究的目的:
- 评估在立法变化后NTS可访问性和质量的改进.
- 评估NTS中"预测的危害"和"不良影响"的报告.
- 为提高NTS实用性提供建议.
主要方法:
- 来自英国和德国的NTS的比较审查.
- 分析的重点是NTS的"不良影响"和"预测伤害"部分.
- 评估报告的完整性与基本要素的对比.
主要成果:
- 在报告六个基本"预测伤害"要素中的五个方面观察到显著的改进.
- 在报告"不良影响"方面没有发现明显的改善.
- 只有41%的德国和48%的英国NTS完全报告了不良影响.
结论:
- 虽然NTS质量有所提高,但报告不良影响仍然是一个关键的差距.
- 研究人员需要在描述动物研究影响时得到支持.
- 增强的NTS对于共享3R最佳实践和告知政策至关重要.
更多相关视频
相关概念视频
Ethics in Research
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...


